Servier and Black Diamond Therapeutics Agree to Global Licensing Deal for BDTX …

e oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, have recently announced a strategic worldwide licensing agreement for BDTX-4933. This collaboration exemplifies Servier’s commitment to creating targeted therapies that cater to unmet medical needs in the field of oncology, especially in addressing various mutations in solid tumors like non-small cell lung cancer.

Servier will take charge of developing and marketing BDTX-4933, a small molecule drug crafted by Black Diamond Therapeutics. It is tailored to treat RAF/RAS-mutant solid tumors in hopes of meeting the needs of patients. Claude Bertrand, the Executive Vice-President of R&D at Servier, expressed enthusiasm about accelerating the development of BDTX-4933 as a potentially groundbreaking treatment option for cancer patients.

Mark Velleca, M.D., Ph.D., the President and CEO of Black Diamond Therapeutics, highlighted their commitment to advancing oral cancer therapies that can enrich the lives of patients and prolong their health. He acknowledged Servier’s enthusiasm and expertise in the oncology field as critical in driving forward the development of revolutionary cancer treatments.

Per the agreement terms, Servier will spearhead the development efforts and worldwide launch of BDTX-4933 across diverse indications, with a primary focus on non-small cell lung cancer. In exchange, Black Diamond Therapeutics will receive an upfront payment of $70 million and could potentially earn up to $710 million in milestone payments tied to development and commercial sales, in addition to royalties based on global net sales.

BDTX-4933, presently in Phase 1 development, uniquely targets RAS and RAF mutations present in solid tumors. The ongoing study seeks to determine the safety profile, recommended Phase 2 dose, and antitumor efficacy of BDTX-4933 in adult patients with recurrent advanced/metastatic cancers carrying specific mutations.

The chief aim of this collaboration is to provide effective and innovative treatment options for cancer patients battling solid tumors. Servier and Black Diamond Therapeutics are unified in their mission to redefine patient care and healthcare outcomes by leveraging cutting-edge targeted therapies like BDTX-4933 in the fight against cancer.

Talking about future prospects

Through this collaboration, Servier and Black Diamond Therapeutics aim to revolutionize cancer care by making targeted therapies like BDTX-4933 accessible to patients in need. The shared vision between the two companies to fill crucial gaps in cancer treatment underscores their dedication to developing and introducing novel treatment options to the oncology landscape. As the partnership progresses, the journey towards transforming cancer care and enhancing patient outcomes remains at the forefront of their endeavors.